DNTH
Price
$20.74
Change
+$0.34 (+1.67%)
Updated
Jul 21 closing price
Capitalization
667M
ERAS
Price
$1.50
Change
-$0.00 (-0.00%)
Updated
Jul 21 closing price
Capitalization
424.93M
16 days until earnings call
Interact to see
Advertisement

DNTH vs ERAS

Header iconDNTH vs ERAS Comparison
Open Charts DNTH vs ERASBanner chart's image
Dianthus Therapeutics
Price$20.74
Change+$0.34 (+1.67%)
Volume$230.32K
Capitalization667M
Erasca
Price$1.50
Change-$0.00 (-0.00%)
Volume$532.49K
Capitalization424.93M
DNTH vs ERAS Comparison Chart in %
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. ERAS commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (DNTH: $20.74 vs. ERAS: $1.50)
Brand notoriety: DNTH and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 73% vs. ERAS: 43%
Market capitalization -- DNTH: $667M vs. ERAS: $424.93M
DNTH [@Biotechnology] is valued at $667M. ERAS’s [@Biotechnology] market capitalization is $424.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than DNTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • DNTH’s TA Score: 5 bullish, 5 bearish.
  • ERAS’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than DNTH.

Price Growth

DNTH (@Biotechnology) experienced а +3.54% price change this week, while ERAS (@Biotechnology) price change was +2.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.39%. For the same industry, the average monthly price growth was +15.71%, and the average quarterly price growth was +33.77%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($667M) has a higher market cap than ERAS($425M). DNTH YTD gains are higher at: -4.862 vs. ERAS (-40.239). DNTH has higher annual earnings (EBITDA): -116.76M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. DNTH (263M). DNTH has less debt than ERAS: DNTH (1.4M) vs ERAS (50.8M). DNTH has higher revenues than ERAS: DNTH (6.52M) vs ERAS (0).
DNTHERASDNTH / ERAS
Capitalization667M425M157%
EBITDA-116.76M-150.24M78%
Gain YTD-4.862-40.23912%
P/E Ratio3.24N/A-
Revenue6.52M0-
Total Cash263M305M86%
Total Debt1.4M50.8M3%
FUNDAMENTALS RATINGS
DNTH: Fundamental Ratings
DNTH
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
PROFIT vs RISK RATING
1..100
56
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
51
P/E GROWTH RATING
1..100
66
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNTHERAS
RSI
ODDS (%)
Bearish Trend 4 days ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
84%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GMGMF0.600.02
+3.99%
Graphene Manufacturing Group Ltd.
EVSYX26.140.04
+0.15%
Allspring Disciplined US Core Admin
AZNCX9.740.01
+0.10%
Virtus Income & Growth C
NRBT0.03N/A
N/A
Novus Robotics, Inc.
NUVSF10.05-0.17
-1.70%
NuVista Energy Ltd.

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+1.67%
IMNM - DNTH
53%
Loosely correlated
+2.27%
XNCR - DNTH
51%
Loosely correlated
+1.45%
ERAS - DNTH
51%
Loosely correlated
N/A
CRNX - DNTH
49%
Loosely correlated
-0.51%
OCUL - DNTH
48%
Loosely correlated
+1.63%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
N/A
RVMD - ERAS
54%
Loosely correlated
+0.31%
XNCR - ERAS
54%
Loosely correlated
+1.45%
OCUL - ERAS
53%
Loosely correlated
+1.63%
BEAM - ERAS
53%
Loosely correlated
+1.35%
ACLX - ERAS
52%
Loosely correlated
+2.67%
More